Lymphocyte function following radium-223 therapy in patients with metastasized, castration-resistant prostate cancer
- 663 Downloads
Therapy with the alpha-emitter radium-223 chloride (223Ra) is an innovative therapeutic option in patients with metastasized, castration-resistant prostate cancer. However, radiotherapy can lead to hematopoietic toxicity. The aim of this study was to determine if 223Ra therapy induces an impairment of cellular antimicrobial immune responses.
In 11 patients receiving 223Ra treatment, lymphocyte proliferation and the production of pro- and anti-inflammatory cytokines (interferon-γ and interleukin-10) were determined, using lymphocyte transformation testing and ELISpot, respectively. Lymphocyte function after stimulation with mitogens and microbial antigens was assessed prior to therapy and at day 1, 7 and 28 after therapy.
Lymphocyte proliferation and the production of interferon-γ and interleukin-10 towards mitogens and antigens remained unchanged after therapy. Consistent with these in vitro data, we did not observe infectious complications after treatment.
The results argue against an impairment of lymphocyte function after 223Ra therapy. Thus, immune responses against pathogens should remain unaffected.
KeywordsRadium-223 therapy Antimicrobial immune response Lymphocyte proliferation ELISpot Cytokine
The authors would like to thank Monika Huben and Martina Praast for their excellent technical assistance.
M.L., V.B., S.P.M., P.A.H. and A.B. contributed to the conception and design of the study. V.B. and M.L. wrote the report. V.B. and D.M. recruited the patients and took blood samples. M.L. and V.B. performed the cellular in vitro assays. All authors read and approved the final manuscript.
Compliance with ethical standards
This study was performed without external funding.
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
- 6.Carrasquillo JA, Donoghue JAO, Pandit-Taskar N, Rathkopf DE, Aksnes A, Viner CL, et al. Phase I pharmacokinetic (PK) and biodistribution study of radium-223 chloride in patients with castration resistant prostate cancer (CRPC) metastatic to bone. J Clin Oncol. 2010;28:Abstract 4680.Google Scholar
- 11.Anderson RE, Lefkovits I. Effects of irradiation on the in vitro immune response. Exp Cell Biol. 1980;48:255–78.Google Scholar
- 15.EXINI Diagnostics. EXINI bone BSI. 2012. http://exini.com/software/exini-bone-bsi/. Accessed July 1 2016.
- 17.Erdi YE, Humm JL, Imbriaco M, Yeung H, Larson SM. Quantitative bone metastases analysis based on image segmentation. J Nucl Med. 1997;38:1401–6.Google Scholar
- 18.Bruland OS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter Ra-223: Adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006;12:6250s-7s.Google Scholar
- 19.Ugurel S, Lindemann M, Schadendorf D, Grosse-Wilde H. Altered surface expression patterns of circulating monocytes in cancer patients: impaired capacity of T-cell stimulation? Cancer Immunol Immunother. 2004;53:1051.Google Scholar